Eye2Gene

Eye2Gene

Private
LondonHealthcare & Life Scienceshttps://eye2gene.com/

Last Round

Seed

Nov 19, 2025

Total Funding Raised

$2.73M

Company Overview

Eye2Gene is a healthcare technology company that has developed a precision ophthalmology platform to improve the diagnosis of genetic eye diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Precision Medicine, Computer Vision, Clinical Trials, Medical Imaging

Business Model

B2B

Customer Profile

Subscription SaaS, Data as a Service, Services & Consulting

AI Layer

Application

Keywords

precision ophthalmologyophthalmology AIinherited retinal diseaseIRDdiagnostic AIretinal imaging AIclinical decision supportpatient stratificationmedical imaging AIrare disease diagnosisclinical trial recruitmentfederated learningCDS softwarecomputer visiongene therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eye2Gene Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Eye2Gene Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
SeedNov 19, 2025
GrantMay 8, 2025
GrantJun 16, 2021

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 19, 2025

    $921K raised with Twin Path Ventures participating.

  • May 8, 2025

    Received grant funding from Medical Research Foundation, Moorfields Eye Charity, and Sight Research UK.

Eye2Gene Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eye2Gene Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eye2Gene's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Year Founded2018
Last FundingNov 19, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.